Dishman Pharmaceuticals and Chemicals has posted strong growth profits due to significant higher other income and lower tax burden during the fourth quarter ended March 2015. Its consolidated net profit went up by 71.6 per cent to Rs.38.77 crore from Rs.22.59 in the corresponding period of last year. Its net, however, improved only by 5 per cent to Rs.421 crore from Rs.401 crore. EPS worked out to Rs.4.80 as against Rs.2.80 in the last period.

The company's other income moved up sharply to Rs.72.71 crore from Rs.16.85 crore and its tax provision declined to Rs.13.97 crore from Rs.27.88 crore. However, its depreciation provision increased to Rs.70.87 crore from Rs.29.12 crore. Interest burden remained almost same at Rs.24.99 crore during the quarter under review.

Dishman's consolidated net sales for the full year ended March 2015 increased by 13.6 per cent to Rs.1,560 crore from Rs.1,373 crore in the previous year. CRAMS sales improved to Rs.1,089 crore from Rs.928 crore. Its net profit improved by 9.8 per cent to Rs.120 crore from Rs.109 crore. EPS worked out to Rs.14.87 as against Rs.13.54 in the previous year.

The company's standalone net sales improved marginally by 1.2 per cent to Rs.477 crore from Rs.472 crore and its net profit declined sharply 32.4 per cent to Rs.58.64 crore from Rs.86.79 crore in the previous year as its tax provision went up to Rs.45.35 crore from Rs.32.05 crore.